Age Related Macular Degeneration News and Research RSS Feed - Age Related Macular Degeneration News and Research

New method identifies preferred retinal locations in both eyes of patients with central vision loss

New method identifies preferred retinal locations in both eyes of patients with central vision loss

Eyes with central vision loss adapt by developing a new fixation point in a different part of the retina, called the preferred retinal location (PRL). Now for the first time, a new method makes it possible to identify PRLs in both eyes simultaneously, reports a study in the August issue of Optometry and Vision Science, official journal of the American Academy of Optometry. [More]
New study suggests novel ways to treat serous retinal detachment

New study suggests novel ways to treat serous retinal detachment

Wet age-related macular degeneration (AMD) is the leading cause of severe vision loss in older individuals. AMD and other serious chronic eye problems that affect younger individuals result when fluid accumulates abnormally under or within the retina. A new study published in The American Journal of Pathology shows for the first time that the release of substances from mast cells may be a causal factor in this type of eye pathology, and inhibitors of this release may offer new ways to treat serous retinal detachment. [More]
Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

For two decades beginning in the late 1970’s through 2001, clinicians relied upon laser photocoagulation in the treatment of wet AMD caused by choroidal neovascularization. Attempts to obliterate the neovascular lesions often led to acute central visual loss and often, even with modest success, the lesions recurred with even more vision loss. [More]
Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

Gene therapy provides life-long protection to photoreceptor cells in animal model of retinitis pigmentosa

A collaboration between scientists in the UK and the USA has shown that gene therapy can give life-long protection to the light-sensitive photoreceptor cells responsible for colour vision in a mouse model of the most common inherited eye disorder. [More]
Up-to-date treatment and diagnostic guidelines for diabetic retinal degeneration

Up-to-date treatment and diagnostic guidelines for diabetic retinal degeneration

Around 600,000 Austrians suffer from diabetes. This condition is frequently associated with serious retinal disorders. Along with age-related macular degeneration, diabetic retinal degeneration is one of the most common causes of blindness. The Department of Ophthalmology and Optometry at MedUni Vienna was chosen by the European Society of Retina Specialists (EURETINA) to coordinate the development of up-to-date treatment and diagnostic guidelines. [More]

Macular atrophy predicts vision in ranibizumab-treated exudative AMD patients

Progression and severity of macular atrophy are the main anatomical determinants of long-term visual outcomes in exudative age-related macular degeneration patients treated with ranibizumab, suggest SEVEN-UP study results. [More]
Researchers compare effectiveness of two stem cell types in treating retinal degeneration

Researchers compare effectiveness of two stem cell types in treating retinal degeneration

By growing two types of stem cells in a "3-D culture" and measuring their ability to produce retinal cells, a team lead by St. Jude Children's Research Hospital researchers has found one cell type to be better at producing retinal cells. [More]

OCT angiography shows promise in CNV detection

Noninvasive optical coherence tomography angiography can successfully detect choroidal neovascularisation, research findings indicate. [More]

Polypoidal choroidal vasculopathy shows distinct classification

Researchers have found that idiopathic polypoidal choroidal vasculopathy has significant clinical differences to neovascular age-related macular degeneration and suggest that it should be considered a distinct entity. [More]

RPE transdifferentiation revealed in AMD

Subducted and melanotic cells in the eyes of patients with advanced age-related macular degeneration derive from two distinct retinal pigment epithelium phenotypes, research shows. [More]

ORT incidence increases in nAMD despite anti-VEGF treatment

Swiss researchers report that patients with neovascular age-related macular degeneration (nAMD) experience increased incidence of outer retinal tubulation over time, despite treatment with a vascular endothelial growth factor blocker. [More]
Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for choroideremia now underway at Royal Alexandra Hospital

Canada's first human gene therapy trial for eyes -- the replacement of a faulty gene with a healthy one -- is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision for people with a genetic disorder that leaves them blind by middle age. [More]
iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics, today announced that all nominees listed in the management information circular dated June 1, 2015 were elected as directors at its 2015 Annual Meeting of Shareholders, held earlier today, June 26 2015. [More]
Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO). [More]
Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron. [More]
Oraya IRay Radiotherapy System for AMD treatment receives Silver award at MDEA 2015

Oraya IRay Radiotherapy System for AMD treatment receives Silver award at MDEA 2015

Oraya Therapeutics Inc.and Bridge Design announced today that the Oraya IRay Radiotherapy System has won the Silver award in the radiological and electromechanical devices category of the 18 Annual Medical Design Excellence Awards (MDEA).The winners were announced at a ceremony in New York City at the Jacob Javits Center in conjunction with the MD&M East event. [More]

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

The Johns Hopkins University and Bayer HealthCare have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases. [More]
Medicare physician reimbursement data could be confusing to the public

Medicare physician reimbursement data could be confusing to the public

The Centers for Medicare & Medicaid Services today released to the public data relating to 2013 Medicare payments made to physicians and other providers. In response, the American Academy of Ophthalmology is providing necessary context for the reimbursement data, which in its raw form are often complex and difficult to understand. [More]

iCo Therapeutics reports financial results for first quarter 2015

iCo Therapeutics, today reported financial results for the quarter ended March 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
Anti-VEGF therapy benefits in wet AMD not sustained

Anti-VEGF therapy benefits in wet AMD not sustained

Real-world experience of anti-vascular endothelial growth factor therapy for patients with wet age-related macular degeneration suggests that initial improvements in visual acuity are not maintained over time. [More]
Advertisement
Advertisement